Jaké bude příští desetiletí kardiologie?

Cor Vasa 2007, 49(4):112 | DOI: 10.33678/cor.2007.044  

Tradiční angiologické dny

Cor Vasa 2007, 49(4):114-115 | DOI: 10.33678/cor.2007.045  

Alpe-Adria Cardiology Meeting Brno, May 13, 2007

Cor Vasa 2007, 49(4):118-120 | DOI: 10.33678/cor.2007.046  

Molekulární kardiologie dnes

Cor Vasa 2007, 49(4):121 | DOI: 10.33678/cor.2007.047  

Několik mýtů o hypertrofické kardiomyopatii

Josef Veselka, David Zemánek

Cor Vasa 2007, 49(4):123-124 | DOI: 10.33678/cor.2007.048  

Is humoral activation in heart failure affected by a genetic predisposition?

Lenka Špinarová, Jindřich Špinar, Anna Vašků, Monika Pávková-Goldbergová, Ondřej Ludka, Josef Tomandl, Jiří Vítovec

Cor Vasa 2007, 49(4):127-133 | DOI: 10.33678/cor.2007.050  

Aim of study:To document an association between the plasma levels of big endothelin and endothelin-1, clinical parameters and the two most frequent polymorphisms (-3A/-4A and G8002A) of the endothelin-1-encoding gene on the one hand and the plasma levels of TNF-a, clinical parameters and the gene polymorphisms of TNF-α -308 A/G, -238 A/G, TNF-β Ncol, and 3 TACE (tumor necrosis factor-a-converting enzyme) in patients with chronic heart failure (HF). Patients and methods:A total of 266 patients with symptomatic HF and documented left ventricular (LV) dysfunction were included. Genotyping was performed and the plasma...

Genetic determination of the prognosis in survivors of acute coronary syndromes. Study design and rationale for a multicenter study

Jan Piťha, Jaroslav A. Hubáček, Rudolf Poledne, Vladimír Staněk, Michael Aschermann, Marie Gebauerová, Petr Hájek, Petr Niederle, Martin Pěnička, Josef Veselka

Cor Vasa 2007, 49(4):134-137 | DOI: 10.33678/cor.2007.051  

Powerful predictors have already been established for clinical complications ensuing from acute coronary events. Despite this, substantial differences exist between patients at apparently similar risk. Amongst the most frequently discussed newer predictors of clinical events are genes and their interactions. Identification of disadvantageous variants of candidate genes could help to detect the patients suitable for more consistent follow-up and the best possible treatment. The two main aims of this study are, first, identification of the particular alleles and genotypes responsible for acute coronary events in a large population of Czech patients in...

Molecular genetics in hypertrophic cardiomyopathy

Karol Čurila, Martin Pěnička, Hana Línková, Jiří Knot, Pavel Gregor

Cor Vasa 2007, 49(4):138-142 | DOI: 10.33678/cor.2007.052  

Hypertrophic cardiomyopathy (HCMP) is a heart disease caused by mutations of the myocardial sarcomere genes. Its most serious complication is sudden death, which could be the first manifestation of this disease. At the other end of the prognosis range are forms with a benign prognosis, without shortening the lifespan of the patient. To date, none of the known factors has been able to identify individuals at the highest risk of sudden death. With the help of molecular genetic methods, gene mutations responsible for the development of HCMP can be recognized prior to the development of myocardial hypertrophy. The clinical picture of the patients is partially...

Depression and the inflammatory state

Alexandra Pilipčincová, Rudolf Poledne

Cor Vasa 2007, 49(4):143-146 | DOI: 10.33678/cor.2007.053  

The importance of depression as a risk factor in the development of cardiovascular disease (CVD) and its complications is well established. The biological mechanism, which could explain this relation remains to be unclear. It has been suggested the link could be chronic inflammation and increased levels of C-reactive protein (CRP), a marker of inflammatory processes. Attempts have been made to verify this hypothesis in a healthy population and, also, in a population with already developed CVD. The acceptance of definitive conclusions in relation to individuals with CVD is complicated by the ambiguity of the relation of cause and consequence and the...

Prevention of cardiovascular complications with paroxetine in individuals with coronary heart disease and depressive/anxiety disorder. The PrevenPar project.

Milan Vrána

Cor Vasa 2007, 49(4):147-151 | DOI: 10.33678/cor.2007.054  

Results of clinical trials have confirmed that depressive/anxiety disorder as another cardiovascular risk factor. The risk is due to enhanced serotonin reuptake by the serotonin transporter. The reuptake not only blocks signal transmission within the brain, it also activates thrombocytes thereby raising the likelihood of thrombogenesis in the presence of coronary heart disease. Another factor affecting the degree of risk is the polymorphism of the serotonin transporter gene (5-HTTLPR) in its promoter segment (SLC6A4). The presence of a short allele (S) decreases the cardiovascular risk conversely increased by the presence of a long allele (L). Of all...

Atypická forma Tako-tsubo kardiomyopatie

Libor Gajdušek, Petr Zajíček, Jan Indrák, Jaroslav Januška, Marian Branny, Libor Škňouřil

Cor Vasa 2007, 49(4):125 | DOI: 10.33678/cor.2007.049  

Tissue factor and the soluble ligand CD40 in patients with acute coronary syndrome

Jan Vojáček, Josef Bis, Jaroslav Dušek, Vladimír Palička, Ctirad Andrys, Miroslav Pecka, Jaroslav Malý

Cor Vasa 2007, 49(4):152-154  

The plasma levels of tissue factor (TF) and the soluble ligand CD40 (sLCD40) were assessed in the coronary sinus (CS), left coronary artery (LCA), and a peripheral vein (PV) of patients with acute coronary syndrome (Group A) and stable coronary artery disease (Group B). Altogether, 28 subjects (age 62.6 ± 10.3 years, 19 males, 9 females) were included into Group A and 24 patients (age 62.3 ± 8.1 years, 21 males, 3 females) into Group B. The plasma levels of sLCD40 were significantly higher in the CS of patients in Group A as compared to those in group B (9070.5 ± 4539.3 pg/mL vs. 6841.4 ± 3283.8 pg/mL, p = 0.026). Also the...